The FDA issued warning letters to 30 telehealth companies over false or misleading claims made about compounded GLP-1 products sold on their websites. It was the second wave of letters aimed at telehealth firms since the agency opened a broader campaign against misleading direct-to-consumer drug advertising in September 2025, and the largest single action against … Read more
The FDA issued over 50 warning letters to US and international companies compounding or manufacturing semaglutide and tirzepatide. The cited conduct centered on marketing compounded GLP-1s as “generic versions” of the approved drugs, or making direct comparative claims against them. Sources: FDA warning letter database · Wilson Sonsini analysis
The FDA established a “green list” import alert covering GLP-1 active pharmaceutical ingredients, intended to stop unverified foreign-sourced APIs from entering the US market. Ingredients from facilities the agency has inspected or evaluated, and which appear to meet its manufacturing standards, are listed; APIs from any other source become subject to detention without physical examination. … Read more
The US District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a preliminary injunction, which had sought to prevent the FDA from keeping tirzepatide off the drug shortage list. Consequential for the compounding market: shortage status is the legal basis for much large-scale compounding of a drug, so the … Read more
The FDA issued a warning letter to USApeptide.com for introducing unapproved and misbranded semaglutide and tirzepatide into interstate commerce. The agency cited inadequate directions for use and pointed to evidence that the products were intended for human applications including weight loss and diabetes management — despite research-use-only labeling. An early instance of the argument the … Read more